Marker Therapeutics Secures $16.2M CPRIT Grant for APOLLO Phase 2
Read source articleWhat happened
Marker Therapeutics has been awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the Phase 2 APOLLO study of MT-601 in CAR-relapsed lymphoma. This non-dilutive funding meaningfully eases the company's tight cash position, which stood at $11.8 million as of June 2025 with runway only into the second quarter of 2026. The grant follows encouraging Phase 1 data showing a 66% overall response rate and 50% complete response rate in heavily pre-treated patients with no severe neurotoxicity. Independent scientific and commercial review by CPRIT adds external validation to Marker's multi-antigen T-cell platform, potentially derisking further development. However, the company still requires substantial additional capital to reach a pivotal trial, so the going-concern risk remains despite this positive step.
Implication
The grant extends Marker's runway and signals external confidence in the APOLLO program, improving the odds of advancing MT-601 without immediate catastrophic dilution. However, investors should note that the grant is milestone-based and covers only a portion of the estimated costs, leaving the company dependent on additional equity or partnership deals to fund the pivotal trial. The strong Phase 1 data and grant support may attract a development partner, but if efficacy degrades in larger cohorts or financing terms become punitive, the investment thesis could break. With a market cap of only $17.6 million and explicit going-concern language, the stock prices in binary risk. For risk-tolerant investors, the grant modestly improves the risk/reward, but position sizing should remain limited given the uncertain clinical and financial path.
Thesis delta
The CPRIT grant is an incremental positive that reinforces the POTENTIAL BUY thesis by reducing near-term financing risk and validating the clinical program. It does not alter the fundamental uncertainty around MT-601's efficacy in larger trials or the need for additional capital, but it modestly increases the probability of successful progression. The overall thesis remains unchanged in direction, with the grant acting as a small tailwind for the company's ability to execute.
Confidence
Moderate